Nota Bene Cancer
Nota Bene Cancer est un bulletin hebdomadaire de veille bibliographique. En libre accès, Nota Bene Cancer permet à ses abonnés de gagner du temps pour se tenir informé de l’actualité scientifique et médicale dans les divers domaines de la recherche sur les cancers.
Rechercher des publications
Pour retrouver les publications signalées par Nota Bene Cancer (archives indexées à partir du n°127 du 1" mars 2012) :
Sommaire du n° 495 du 13 juillet 2021
Lutte contre les cancers
Qualité de vie, soins de support (1)
Menée auprès de 155 patients âgés atteints d'un cancer de la prostate métastatique résistant à la castration (âge : au moins 65 ans), cette étude analyse l'effet, sur la fonction cognitive, des traitements par docétaxel, abiratérone, enzalutamide ou radium 223
Association of Chemotherapy, Enzalutamide, Abiraterone, and Radium 223 With Cognitive Function in Older Men With Metastatic Castration-Resistant Pr...
Menée auprès de 155 patients âgés atteints d'un cancer de la prostate métastatique résistant à la castration (âge : au moins 65 ans), cette étude analyse l'effet, sur la fonction cognitive, des traitements par docétaxel, abiratérone, enzalutamide ou radium 223
Association of Chemotherapy, Enzalutamide, Abiraterone, and Radium 223 With Cognitive Function in Older Men With Metastatic Castration-Resistant Prostate Cancer
Alibhai, Shabbir M. H. ; Breunis, Henriette ; Feng, Gregory ; Timilshina, Narhari ; Hansen, Aaron ; Warde, Padraig ; Gregg, Richard ; Joshua, Anthony ; Fleshner, Neil ; Tomlinson, George ; Emmenegger, Urban
Older adults are at greater risk of cognitive decline with various oncologic therapies. Some commonly used therapies for advanced prostate cancer, such as enzalutamide, have been linked to cognitive impairment, but published data are scarce, come from single-group studies, or focus on self-reported cognition.To longitudinally examine the association between cognitive function and docetaxel (chemotherapy), abiraterone, enzalutamide, and radium Ra 223 dichloride (radium 223) in older men with [...]
Observation (16)
Menée en Allemagne par questionnaire auprès de 6 952 patients ayant survécu à un cancer du sein, un cancer de la prostate ou un cancer colorectal (âge moyen : 69 ans), cette étude évalue leur croissance post-traumatique, par type de cancer, par âge et en fonction du sexe
Prevalence of benefit finding and posttraumatic growth in long-term cancer survivors: results from a multi-regional population-based survey in Germany
Menée en Allemagne par questionnaire auprès de 6 952 patients ayant survécu à un cancer du sein, un cancer de la prostate ou un cancer colorectal (âge moyen : 69 ans), cette étude évalue leur croissance post-traumatique, par type de cancer, par âge et en fonction du sexe
Prevalence of benefit finding and posttraumatic growth in long-term cancer survivors: results from a multi-regional population-based survey in Germany
Liu, Zhunzhun ; Thong, Melissa S. Y. ; Doege, Daniela ; Koch-Gallenkamp, Lena ; Bertram, Heike ; Eberle, Andrea ; Holleczek, Bernd ; Waldmann, Annika ; Zeissig, Sylke Ruth ; Pritzkuleit, Ron ; Brenner, Hermann ; Arndt, Volker
Background: Cancer studies reported mixed results on benefit finding (BF) and posttraumatic growth (PTG) prevalence and few were focused on long-term survivors. Methods: BF and PTG were assessed in a multi-regional population-based study in Germany with 6952 breast, colorectal and prostate cancer survivors, using the Benefit Finding Scale and Posttraumatic Growth Inventory. We calculated the age-adjusted prevalence, stratified by demographical and clinical characteristics. Results: Overall, [...]
Menée en Allemagne sur la période 2015-2016 auprès de 167 patients atteints d'un cancer du poumon (âge médian : 66 ans ; 63 % d'hommes), cette étude évalue la fréquence des auto-anticorps neuronaux et analyse leur association avec le risque de troubles cognitifs
Association Between Neuronal Autoantibodies and Cognitive Impairment in Patients With Lung Cancer
Menée en Allemagne sur la période 2015-2016 auprès de 167 patients atteints d'un cancer du poumon (âge médian : 66 ans ; 63 % d'hommes), cette étude évalue la fréquence des auto-anticorps neuronaux et analyse leur association avec le risque de troubles cognitifs
Association Between Neuronal Autoantibodies and Cognitive Impairment in Patients With Lung Cancer
Bartels, Frederik ; Wandrey, Mona-Marie ; Aigner, Annette ; Strönisch, Timo ; Farmer, Kimberley ; Rentzsch, Kristin ; Tessmer, Antje ; Grohe, Christian ; Finke, Carsten
Paraneoplastic neurological syndromes are associated with neuronal autoantibodies, and some of these autoantibodies are associated with neuropsychological symptoms. The most common underlying tumor is lung cancer. The association of neuronal autoantibodies with cognitive deficits has not been systematically investigated in patients with small cell lung cancer (SCLC) and non–small cell lung cancer (NSCLC).To assess the frequency of neuronal autoantibodies in patients with lung cancer and analyze [...]
Unravelling the Mechanisms of Cancer-Related Cognitive Dysfunction in Non–Central Nervous System Cancer
Menée en Allemagne sur la période 2015-2016 auprès de 167 patients atteints d'un cancer du poumon (âge médian : 66 ans ; 63 % d'hommes), cette étude évalue la fréquence des auto-anticorps neuronaux et analyse leur association avec le risque de troubles cognitifs
Unravelling the Mechanisms of Cancer-Related Cognitive Dysfunction in Non–Central Nervous System Cancer
Hervey-Jumper, Shawn L. ; Monje, Michelle
Over the past 30 years, a growing body of evidence has emerged demonstrating that many patients with systemic cancer experience cancer-related cognitive impairments (CRCIs). Difficulties with memory, language, learning, attention, and processing speed (outside of that which would be expected because of normal aging) are increasingly observed among long-term survivors of cancer. Traditionally, CRCI symptoms were thought to be caused only by the neurotoxic effects of cancer therapies; therefore, [...]
Menée aux Etats-Unis à l'aide de données 2010-2014 portant sur 146 418 et 178 688 adolescents et jeunes adultes atteints d'un cancer (âge : 15-39 ans), cette étude analyse l'association entre la zone géographique de résidence au moment du diagnostic (métropolitaine, urbaine ou rurale), la distance avec l'hôpital et le stade au diagnostic ou la survie
Associations between geographic residence and US adolescent and young adult cancer stage and survival
Menée aux Etats-Unis à l'aide de données 2010-2014 portant sur 146 418 et 178 688 adolescents et jeunes adultes atteints d'un cancer (âge : 15-39 ans), cette étude analyse l'association entre la zone géographique de résidence au moment du diagnostic (métropolitaine, urbaine ou rurale), la distance avec l'hôpital et le stade au diagnostic ou la survie
Associations between geographic residence and US adolescent and young adult cancer stage and survival
Johnson, Kimberly J. ; Wang, Xiaoyan ; Barnes, Justin M. ; Delavar, Arash
Background: Multiple studies have indicated that place of residence can influence cancer survival; however, few studies have specifically focused on geographic factors and outcomes in adolescents and young adults (AYAs) with cancer. The objective of this study was to evaluate evidence for geographic disparities in cancer diagnosis stage and overall survival in AYAs and to examine whether stage mediated survival associations. Methods: National Cancer Database data on AYAs aged 15 to 39 years who [...]
The role of geographic distance from a cancer center in survival and stage of AYA cancer diagnoses
Menée aux Etats-Unis à l'aide de données 2010-2014 portant sur 146 418 et 178 688 adolescents et jeunes adultes atteints d'un cancer (âge : 15-39 ans), cette étude analyse l'association entre la zone géographique de résidence au moment du diagnostic (métropolitaine, urbaine ou rurale), la distance avec l'hôpital et le stade au diagnostic ou la survie
The role of geographic distance from a cancer center in survival and stage of AYA cancer diagnoses
Darlington, Wendy S. ; Green, Adam L.
In this editorial, the authors examine the current understanding of geographic differences affecting outcomes for adolescent and young adult patients with cancer and explore future directions to potentially mitigate these effects.
Menée à l'aide de données 2012-2016 d'un registre chinois portant sur 549 patients atteints d'une leucémie myéloïde aiguë à risque intermédiaire de récidive (âge médian : 37 ans ; 57 % d'hommes), cette étude analyse l'association entre les traitements reçus (chimiothérapie, greffe de cellules souches autologues ou allogreffe de cellules souches) et la maladie résiduelle dynamique mesurable
Association Between Measurable Residual Disease in Patients With Intermediate-Risk Acute Myeloid Leukemia and First Remission, Treatment, and Outcomes
Menée à l'aide de données 2012-2016 d'un registre chinois portant sur 549 patients atteints d'une leucémie myéloïde aiguë à risque intermédiaire de récidive (âge médian : 37 ans ; 57 % d'hommes), cette étude analyse l'association entre les traitements reçus (chimiothérapie, greffe de cellules souches autologues ou allogreffe de cellules souches) et la maladie résiduelle dynamique mesurable
Association Between Measurable Residual Disease in Patients With Intermediate-Risk Acute Myeloid Leukemia and First Remission, Treatment, and Outcomes
Yu, Sijian ; Fan, Zhiping ; Ma, Liping ; Wang, Yu ; Huang, Fen ; Zhang, Qing ; Huang, Jiafu ; Wang, Shunqing ; Xu, Na ; Xuan, Li ; Xiong, Mujun ; Han, Lijie ; Sun, Zhiqiang ; Zhang, Hongyu ; Liu, Hui ; Yu, Guopan ; Shi, Pengcheng ; Xu, Jun ; Wu, Meiqing ; Guo, Ziwen ; Xiong, Yiying ; Duan, Chongyang ; Sun, Jing ; Liu, Qifa ; Zhang, Yu
Measurable residual disease (MRD) is widely used as a therapy-stratification factor for acute myeloid leukemia (AML), but the association of dynamic MRD with postremission treatment (PRT) in patients with intermediate-risk AML (IR-AML) has not been well investigated.To investigate PRT choices based on dynamic MRD in patients with IR-AML.This cohort study examined 549 younger patients with de novo IR-AML in the South China Hematology Alliance database during the period from January 1, 2012, to [...]
Menée à partir de données des registres américains des cancers portant sur 15 899 patients adolescents ou jeunes adultes ayant survécu au moins 5 ans après un lymphome hodgkinien diagnostiqué entre 1980 et 2009 (durée médiane de suivi : 14,4 ans), cette étude analyse l'association entre l'origine ethnique, le statut socioéconomique, le cadre de vie, l'âge ou le stade au diagnostic et la survie à long terme
Impact of race, ethnicity and socioeconomic status over time on the long-term survival of adolescent and young adult Hodgkin lymphoma survivors
Menée à partir de données des registres américains des cancers portant sur 15 899 patients adolescents ou jeunes adultes ayant survécu au moins 5 ans après un lymphome hodgkinien diagnostiqué entre 1980 et 2009 (durée médiane de suivi : 14,4 ans), cette étude analyse l'association entre l'origine ethnique, le statut socioéconomique, le cadre de vie, l'âge ou le stade au diagnostic et la survie à long terme
Impact of race, ethnicity and socioeconomic status over time on the long-term survival of adolescent and young adult Hodgkin lymphoma survivors
Berkman, Amy M ; Andersen, Clark R ; Puthenpura, Vidya ; Livingston, J. Andrew ; Ahmed, Sairah ; Cuglievan, Branko ; Hildebrandt, Michelle A.T. ; Roth, Michael E.
Background: While there are growing numbers of adolescent and young adult (AYA) Hodgkin's lymphoma (HL) survivors, long-term overall survival (OS) patterns and disparities in this population are underreported. The aim of the current study was to assess the impact of race/ethnicity, socioeconomic status (SES), rurality, diagnosis age, sex, and HL stage over time on long-term survival in AYA HL survivors. Methods: The authors used the Surveillance, Epidemiology, and End Results (SEER) registry to [...]
Menée à l'aide de données 2007-2015 des registres américains des cancers portant sur 4 533 patients âgés atteints d'un myélome multiple (âge moyen : 75,8 ans), cette étude analyse les coûts supplémentaires à vie pour l'assurance maladie payante Medicare, en fonction de la phase de soins (prédiagnostic, soins initiaux, soins continus et phase terminale)
Phase-Specific and Lifetime Costs of Multiple Myeloma Among Older Adults in the US
Menée à l'aide de données 2007-2015 des registres américains des cancers portant sur 4 533 patients âgés atteints d'un myélome multiple (âge moyen : 75,8 ans), cette étude analyse les coûts supplémentaires à vie pour l'assurance maladie payante Medicare, en fonction de la phase de soins (prédiagnostic, soins initiaux, soins continus et phase terminale)
Phase-Specific and Lifetime Costs of Multiple Myeloma Among Older Adults in the US
Bhattacharya, Kaustuv ; Bentley, John P. ; Ramachandran, Sujith ; Chang, Yunhee ; Banahan, Benjamin F., III ; Shah, Ruchit ; Bhakta, Nickhill ; Yang, Yi
Health care costs associated with diagnosis and care among older adults with multiple myeloma (MM) are substantial, with cost of care and the factors involved differing across various phases of the disease care continuum, yet little is known about cost of care attributable to MM from a Medicare perspective.To estimate incremental phase-specific and lifetime costs and cost drivers among older adults with MM enrolled in fee-for-service Medicare.A retrospective cohort study was conducted using [...]
Menée auprès de 1 005 patients atteints d'un cancer du poumon (55 % de femmes ; 33 % non fumeurs), cette étude analyse les facteurs de risque associés à la maladie chez les patients n'ayant jamais fumé
High Ambient Air Pollution Exposure Among Never Smokers Versus Ever Smokers with Lung Cancer
Menée auprès de 1 005 patients atteints d'un cancer du poumon (55 % de femmes ; 33 % non fumeurs), cette étude analyse les facteurs de risque associés à la maladie chez les patients n'ayant jamais fumé
High Ambient Air Pollution Exposure Among Never Smokers Versus Ever Smokers with Lung Cancer
Myers, Renelle ; Brauer, Michael ; Dummer, Trevor ; Atkar-Khattra, Sukhinder ; Yee, John ; Melosky, Barbara ; Ho, Cheryl ; McGuire, Anna L. ; Sun, Sophie ; Grant, Kyle ; Lee, Alexander ; Lee, Martha ; Yuchi, Weiran ; Tammemagi, Martin ; Lam, Stephen
Background: Air pollution may play an important role in development of lung cancers in people who have never smoked, especially among East Asian women. The aim of this study was to compare cumulative ambient air pollution exposure between ever and never smokers with lung cancer. Methods: A consecutive cases series of never and ever smokers with newly diagnosed lung cancer were compared regarding their sex, race, outdoor and household air pollution exposure. Using individual residential history, [...]
A partir d'une revue systématique de la littérature publiée entre janvier 2000 et juillet 2020 (28 articles), cette étude analyse les disparités ethniques dans la survie globale et la survie spécifique des patients atteints d'un cancer du poumon
Ethnic Differences in Survival Among Lung Cancer Patients: A Systematic Review
A partir d'une revue systématique de la littérature publiée entre janvier 2000 et juillet 2020 (28 articles), cette étude analyse les disparités ethniques dans la survie globale et la survie spécifique des patients atteints d'un cancer du poumon
Ethnic Differences in Survival Among Lung Cancer Patients: A Systematic Review
Price, Sarah N ; Flores, Melissa ; Hamann, Heidi A ; Ruiz, John M
Despite a substantially worse risk factor profile, Hispanics in the United States experience lower incidence of many diseases and longer survival than non-Hispanic Whites (NHWs), an epidemiological phenomenon known as the Hispanic Health Paradox (HHP). This systematic review evaluated the published longitudinal literature to address whether this pattern extends to lung cancer survival.Searches of Medline, PubMed, Embase, Web of Science, and the Cochrane Library were conducted for January 1, [...]
A partir d'une revue systématique de la littérature publiée jusqu'en décembre 2020 (7 études, 6 essais randomisés, 391 patients), cette méta-analyse évalue l'effet, sur la fonction physique et les effets indésirables liés au traitement, de la pratique d'une activité physique pendant la radiothérapie chez les patients atteints d'un cancer de la prostate
Effects of exercise during radiotherapy on physical function and treatment-related side effects in men with prostate cancer: a systematic review an...
A partir d'une revue systématique de la littérature publiée jusqu'en décembre 2020 (7 études, 6 essais randomisés, 391 patients), cette méta-analyse évalue l'effet, sur la fonction physique et les effets indésirables liés au traitement, de la pratique d'une activité physique pendant la radiothérapie chez les patients atteints d'un cancer de la prostate
Effects of exercise during radiotherapy on physical function and treatment-related side effects in men with prostate cancer: a systematic review and meta-analysis
Schumacher, Oliver ; Luo, Hao ; Taaffe, Dennis R. ; Galvão, Daniel A. ; Tang, Colin ; Chee, Raphael ; Spry, Nigel ; Newton, Robert U.
Background: Radiotherapy is a commonly used treatment for prostate cancer; however, the side effects may negatively impact on quality of life and cause patients to be less physically active. While exercise has been shown to mitigate radiotherapy-related fatigue in men with prostate cancer during radiotherapy, other adverse effects of treatment such as physical deconditioning, urinary symptoms or sexual dysfunction have not been systematically reviewed in this patient population. Thus, the [...]
Menée à partir de données 2004-2016 portant sur 248 634 patients, cette étude compare les modalités des traitements reçus et la survie globale des patients atteints d'un cancer du pancréas développé avant ou après l'âge de 50 ans
Treatment patterns and survival in patients with early-onset pancreatic cancer
Menée à partir de données 2004-2016 portant sur 248 634 patients, cette étude compare les modalités des traitements reçus et la survie globale des patients atteints d'un cancer du pancréas développé avant ou après l'âge de 50 ans
Treatment patterns and survival in patients with early-onset pancreatic cancer
Saadat, Lily V. ; Chou, Joanne F. ; Gonen, Mithat ; Soares, Kevin C. ; Kingham, T. Peter ; Varghese, Anna M. ; Jarnagin, William R. ; D’Angelica, Michael I. ; Drebin, Jeffrey A. ; O’Reilly, Eileen M. ; Wei, Alice C.
BACKGROUND: Pancreatic cancer is uncommon in patients younger than 50 years, although its incidence is increasing. This study characterizes treatment utilization for early-onset pancreatic cancer (EOPC) versus average-age-onset pancreatic cancer (AOPC) and identifies factors associated with failure to receive treatment. METHODS: The National Cancer Data Base (NCDB) was queried for patients with EOPC (age < 50 years) or AOPC (age ≥ 50 years) from 2004 to 2016. Multinomial regression was used to [...]
Menée en Suède à partir de données 2006-2012 d'un registre des médicaments prescrits portant sur 32 411 patients atteints d'un cancer colorectal, cette étude analyse l'association entre une utilisation d'inhibiteurs de la pompe à protons et la mortalité spécifique et toutes causes confondues (4 746 décès)
Proton pump inhibitors and survival in patients with colorectal cancer: a Swedish population-based cohort study
Menée en Suède à partir de données 2006-2012 d'un registre des médicaments prescrits portant sur 32 411 patients atteints d'un cancer colorectal, cette étude analyse l'association entre une utilisation d'inhibiteurs de la pompe à protons et la mortalité spécifique et toutes causes confondues (4 746 décès)
Proton pump inhibitors and survival in patients with colorectal cancer: a Swedish population-based cohort study
Wang, Xinchen ; Liu, Qing ; Halfdanarson, Óskar Ö ; Zoega, Helga ; Sadr-Azodi, Omid ; Engstrand, Lars ; Fall, Katja ; Brusselaers, Nele
Background: Proton pump inhibitors (PPIs) are associated with microbiome changes of the gut, which in turn may affect the progression of colorectal cancer (CRC). This study aims to assess the associations between PPI use and all-cause and CRC-specific mortality. Methods: We selected all patients registered in the Swedish Prescribed Drug Registry who were diagnosed with CRC between 2006 and 2012 (N = 32,411, 54.9% PPI users) and subsequently followed them through register linkage to the Swedish [...]
Ce dossier présente un ensemble d'articles concernant la prise en charge des cancers durant la crise sanitaire liée au COVID-19
Serologic Status and Toxic Effects of the SARS-CoV-2 BNT162b2 Vaccine in Patients Undergoing Treatment for Cancer
Ce dossier présente un ensemble d'articles concernant la prise en charge des cancers durant la crise sanitaire liée au COVID-19
Serologic Status and Toxic Effects of the SARS-CoV-2 BNT162b2 Vaccine in Patients Undergoing Treatment for Cancer
Goshen-Lago, Tal ; Waldhorn, Ithai ; Holland, Roy ; Szwarcwort-Cohen, Moran ; Reiner-Benaim, Anat ; Shachor-Meyouhas, Yael ; Hussein, Khetam ; Fahoum, Liana ; Baruch, Mali ; Peer, Avivit ; Reiter, Yoram ; Almog, Ronit ; Halberthal, Michael ; Ben-Aharon, Irit
The efficacy and safety profile of SARS-CoV-2 vaccines have been acquired from phase 3 studies; however, patients with cancer were not represented in these trials. Owing to the recommendation to prioritize high-risk populations for vaccination, further data are warranted.To evaluate the use and safety of the BNT162b2 vaccine in patients undergoing treatment for cancer.In January 2021, mass SARS-CoV-2 vaccination of high-risk populations, including patients with cancer, was initiated in Israel. [...]
Immune responses to COVID-19 vaccines in patients with cancer: Promising results and a note of caution
Ce dossier présente un ensemble d'articles concernant la prise en charge des cancers durant la crise sanitaire liée au COVID-19
Immune responses to COVID-19 vaccines in patients with cancer: Promising results and a note of caution
Griffiths, Elizabeth A. ; Segal, Brahm H.
SARS-CoV-2 vaccines are effective in preventing COVID-19. Patients with cancer are at high risk for severe COVID-19 and are appropriately prioritized for vaccination. Several studies in this issue of Cancer Cell add to our knowledge of the heterogeneity of immune responses to vaccination among patients with cancer and identify important areas for future research.
Plitidepsin for the management of a cancer patient infected with SARS-CoV-2 while receiving chemotherapy
Ce dossier présente un ensemble d'articles concernant la prise en charge des cancers durant la crise sanitaire liée au COVID-19
Plitidepsin for the management of a cancer patient infected with SARS-CoV-2 while receiving chemotherapy
Guisado-Vasco, P. ; González-Cortijo, L. ; D’Errico, G. ; Serrera-Alvarez, A. ; Sotres-Fernandez, G. ; García-Coca, M. ; Fernández-Sousa, J. M. ; Luepke-Estefan, X. E. ; López-Martín, J. A. ; Jimeno, J. M.
Plitidepsin is a cyclic peptide that inhibits the host protein elongation factor alpha 1, thus blocking viral replication. A hospitalized patient with stage IIIB gastric signet ring cell carcinoma and multiple comorbidities developed Coronavirus disease (COVID-19) shortly after receiving his first chemotherapy course. He was treated with plitidepsin on a compassionate use basis. The patient showed a substantial acute reduction in viral load 4 days after initiating plitidepsin treatment and was [...]
Immunogenicity of a heterologous COVID-19 vaccine after failed vaccination in a lymphoma patient
Ce dossier présente un ensemble d'articles concernant la prise en charge des cancers durant la crise sanitaire liée au COVID-19
Immunogenicity of a heterologous COVID-19 vaccine after failed vaccination in a lymphoma patient
Hill, Joshua A. ; Ujjani, Chaitra S. ; Greninger, Alexander L. ; Shadman, Mazyar ; Gopal, Ajay K.
We read with great interest the recent publications in Cancer Cell regarding seroconversion rates following SARS-CoV-2 vaccination among patients with cancer (Addeo et al., 2021; Thakkar et al., 2021). Both studies demonstrated that a lower proportion of patients with hematologic malignancies seroconverted. Additionally, these individuals had lower absolute antibody titers. Similar data have emerged from other studies, some showing even lower seroconversion rates of 50%–60% in patients with [...]
Blunted humoral response after mRNA vaccine in patients with haematological malignancies
Ce dossier présente un ensemble d'articles concernant la prise en charge des cancers durant la crise sanitaire liée au COVID-19
Blunted humoral response after mRNA vaccine in patients with haematological malignancies
Kamboj, Mini
Patients with haematological malignancies are at a higher risk for severe COVID-19 outcomes than healthy individuals. These patients can also have long-term direct and indirect clinical consequences of SARS-CoV-2 infection, including stalled cancer care. Therefore, to reduce the impact of COVID-19 on this clinically vulnerable population, optimal vaccine protection is paramount. The COVID-19 mRNA vaccines produce a robust adaptive immune response in healthy individuals and have been a [...]
Recovery of cancer screening tests and possible associated disparities after the first peak of the COVID-19 pandemic
Ce dossier présente un ensemble d'articles concernant la prise en charge des cancers durant la crise sanitaire liée au COVID-19
Recovery of cancer screening tests and possible associated disparities after the first peak of the COVID-19 pandemic
Labaki, Chris ; Bakouny, Ziad ; Schmidt, Andrew ; Lipsitz, Stuart R. ; Rebbeck, Timothy R. ; Trinh, Quoc-Dien ; Choueiri, Toni K.
Following the pandemic onset, a dramatic decrease in the number of cancer screening tests and ensuing diagnoses was observed (Bakouny et al., 2021; Chen et al., 2021; Patt et al., 2020). The consequent delays in diagnosis are expected to result in adverse oncologic outcomes (Hartman et al., 2020; Maringe et al., 2020). It is unknown to what extent screening pathways adapted during the pandemic, enabling the recovery of missed diagnoses.
Antibody responses after SARS-CoV-2 vaccination in patients with lymphoma
Ce dossier présente un ensemble d'articles concernant la prise en charge des cancers durant la crise sanitaire liée au COVID-19
Antibody responses after SARS-CoV-2 vaccination in patients with lymphoma
Lim, Sean H. ; Campbell, Nicola ; Johnson, Marina ; Joseph-Pietras, Debora ; Collins, Graham P. ; O'Callaghan, Ann ; Fox, Christopher P. ; Ahearne, Matthew ; Johnson, Peter W. M. ; Goldblatt, David ; Davies, Andrew J.
Individuals with lymphoid malignancies are at risk of developing severe COVID-19 and are less likely to develop protective immune responses to SARS-CoV-2 vaccination than the general population because of disease-related or treatment-related immunosuppression. Data on vaccine responses in chronic lymphocytic leukaemia have shown antibody responses in 52–75% of individuals after the second dose.1, 2 Vaccine responses after two doses in people with other lymphoid malignancies remain undefined. In [...]
Immunogenicity of the BNT162b2 COVID-19 mRNA vaccine and early clinical outcomes in patients with haematological malignancies in Lithuania: a natio...
Ce dossier présente un ensemble d'articles concernant la prise en charge des cancers durant la crise sanitaire liée au COVID-19
Immunogenicity of the BNT162b2 COVID-19 mRNA vaccine and early clinical outcomes in patients with haematological malignancies in Lithuania: a national prospective cohort study
Maneikis, Kazimieras ; Šablauskas, Karolis ; Ringelevičiūtė, Ugnė ; Vaitekėnaitė, Vilmantė ; Čekauskienė, Rita ; Kryžauskaitė, Lina ; Naumovas, Daniel ; Banys, Valdas ; Pečeliūnas, Valdas ; Beinortas, Tumas ; Griškevičius, Laimonas
Background : Haematological malignancies and their treatments are likely to affect SARS-CoV-2 vaccine efficacy. We aimed to evaluate serological response to BNT162b2 vaccine in patients with haematological malignancies by type of treatment. Methods : Our national prospective cohort study was done in Lithuania and assessed serological response to one and two BNT162b2 (Comirnaty, Pfizer-BioNTech) vaccine doses in healthy health-care workers and in patients with haematological malignancies. [...]
Highly variable SARS-CoV-2 spike antibody responses to two doses of COVID-19 RNA vaccination in patients with multiple myeloma
Ce dossier présente un ensemble d'articles concernant la prise en charge des cancers durant la crise sanitaire liée au COVID-19
Highly variable SARS-CoV-2 spike antibody responses to two doses of COVID-19 RNA vaccination in patients with multiple myeloma
Van Oekelen, Oliver ; Gleason, Charles R. ; Agte, Sarita ; Srivastava, Komal ; Beach, Katherine F. ; Aleman, Adolfo ; Kappes, Katerina ; Banu, Radhika ; Bermúdez-González, Maria C. ; Chernet, Rachel L. ; Ferreri, Emily D. ; Floda, Daniel L. ; Firpo-Betancourt, Adolfo ; Kleiner, Giulio ; Russo, Kayla T. ; Salimbangon, Ashley-Beathrese T. ; Saksena, Miti S. ; Shin, Amber A. ; Matthews, Julia ; Mendez, Wanni ; Sominsky, Levy ; Mulder, Lubbertus C. F. ; Mendu, Rao ; Mouhieddine, Tarek H. ; Wang, Bo ; Chari, Ajai ; Cordon-Cardo, Carlos ; Krammer, Florian ; Jagannath, Sundar ; Simon, Viviana ; Wajnberg, Ania ; Parekh, Samir
COVID-19 mRNA vaccines are highly efficacious in preventing COVID-19 morbidity and mortality in phase 3 clinical studies as well as in real-world settings. Emerging evidence suggests that some individuals with underlying comorbidities may mount suboptimal antibody responses to SARS-CoV-2 immunization (Addeo et al., 2021; Monin et al., 2021; Thakkar et al., 2021). Indeed, patients with multiple myeloma (MM) are immuno-compromised due to defects in humoral and cellular immunity as well as due to [...]
A partir d'une revue systématique de la littérature publiée jusqu'en janvier 2020 (39 études), cette méta-analyse évalue les effets d'une grossesse chez des femmes ayant survécu à un cancer du sein
Pregnancy After Breast Cancer: A Systematic Review and Meta-Analysis
A partir d'une revue systématique de la littérature publiée jusqu'en janvier 2020 (39 études), cette méta-analyse évalue les effets d'une grossesse chez des femmes ayant survécu à un cancer du sein
Pregnancy After Breast Cancer: A Systematic Review and Meta-Analysis
Matteo Lambertini ; Eva Blondeaux ; Marco Bruzzone ; Marta Perachino ; Richard A. Anderson ; Evandro de Azambuja ; Philip D. Poorvu ; Hee Jeong Kim ; Cynthia Villarreal-Garza ; Barbara Pistilli ; Ines Vaz-Luis ; Cristina Saura ; Kathryn J. Ruddy ; Maria Alice Franzoi ; Chiara Sertoli ; Marcello Ceppi ; Hatem A. Azim Jr ; Frederic Amant ; Isabelle Demeestere ; Lucia Del Mastro ; Ann H. Partridge ; Olivia Pagani ; Fedro A. Peccatori
PURPOSE: Many patients and physicians remain concerned about the potential detrimental effects of pregnancy after breast cancer (BC) in terms of reproductive outcomes and maternal safety. This systematic review and meta-analysis aimed at providing updated evidence on these topics. METHODS: A systematic literature review was conducted to identify studies including patients with a pregnancy after BC (PROSPERO number CRD42020158324). Likelihood of pregnancy after BC, their reproductive outcomes, [...]
Menée en Amérique du Nord auprès de 9 087 patients pédiatriques atteints d'un neuroblastome à risque intermédiaire ou élevé de récidive (âge moyen : 11-46 mois), cette étude analyse l'association entre la participation à un essai clinique et la survie sans événement ou la survie globale
Association Between Participation in Clinical Trials and Overall Survival Among Children With Intermediate- or High-risk Neuroblastoma
Menée en Amérique du Nord auprès de 9 087 patients pédiatriques atteints d'un neuroblastome à risque intermédiaire ou élevé de récidive (âge moyen : 11-46 mois), cette étude analyse l'association entre la participation à un essai clinique et la survie sans événement ou la survie globale
Association Between Participation in Clinical Trials and Overall Survival Among Children With Intermediate- or High-risk Neuroblastoma
Balyasny, Skye ; Lee, Sang Mee ; Desai, Ami V. ; Volchenboum, Samuel L. ; Naranjo, Arlene ; Park, Julie R. ; London, Wendy B. ; Cohn, Susan L. ; Applebaum, Mark A.
Participants in clinical trials may experience benefits associated with new therapeutic strategies as well as tight adherence to best supportive care practices.To investigate whether participation in a clinical trial is associated with improved survival among children with neuroblastoma and investigate potential recruitment bias of patients in clinical trials.This cohort study included pediatric patients with intermediate- or high-risk neuroblastoma in North American studies who were included [...]
Menée aux Etats-Unis à partir de données 2013-2017, cette étude analyse l'évolution de l'incidence et de la mortalité des cancers des voies biliaires, par région, âge, sexe, origine ethnique et stade au diagnostic
Incidence and mortality of cancers of the biliary tract by sex, age, race/ethnicity, and stage at diagnosis-United States, 2013-2017
Menée aux Etats-Unis à partir de données 2013-2017, cette étude analyse l'évolution de l'incidence et de la mortalité des cancers des voies biliaires, par région, âge, sexe, origine ethnique et stade au diagnostic
Incidence and mortality of cancers of the biliary tract by sex, age, race/ethnicity, and stage at diagnosis-United States, 2013-2017
Ellington, Taylor D ; Momin, Behnoosh ; Wilson, Reda J. ; Henley, S. Jane ; Wu, Manxia ; Ryerson, A. Blythe
Background: Few population-based studies have examined incidence and mortality of cancers of the biliary tract, including intrahepatic bile duct, extrahepatic bile duct, ampulla of Vater, and overlapping or other lesion of the biliary tract in one study. Methods: To further the understanding of recent rates of biliary tract cancers, we used population-based data, to examine incidence and mortality during 2013-2017. We examined how rates varied by sex, age, race/ethnicity, U.S. census region, [...]
Menée entre 2013 et 2016 auprès de 267 patients atteints d'un carcinome du rhinopharynx, cette étude analyse l'association entre leur état dépressif et d'anxiété avant la radiothérapie et les toxicités aiguës liées aux rayonnements
Anxiety and depression status prior to radiotherapy in patients with nasopharyngeal carcinoma and its effect on acute radiation toxicities
Menée entre 2013 et 2016 auprès de 267 patients atteints d'un carcinome du rhinopharynx, cette étude analyse l'association entre leur état dépressif et d'anxiété avant la radiothérapie et les toxicités aiguës liées aux rayonnements
Anxiety and depression status prior to radiotherapy in patients with nasopharyngeal carcinoma and its effect on acute radiation toxicities
Li, Rong ; Su, Li ; Hua, Yangjingling ; Ye, Jin-Ru ; Song, Xiu-Rong ; Tian, Jun ; Song, Ji-Hong ; Hong, Jin-Sheng
Objective: The objective of this work is to explore anxiety and depression status prior to radiotherapy in patients with nasopharyngeal carcinoma (NPC) and its effect on acute radiation toxicities. Methods: A total of 267 NPC patients were enrolled between August 2013 and September 2016. The anxiety and depression status of the patients prior to radiotherapy was evaluated using the Hospital Anxiety and Depression Scale. Acute radiation toxicities were assessed weekly and recorded according to [...]
Analyses économiques et systèmes de soins (2)
Menée à partir de données 2008-2013 de l'Assurance maladie allemande portant sur 1 909 patients atteints d'un cancer du côlon, cette étude compare le rapport coût-efficacité des soins en cancérologie dans des hopitaux certifiés ou non
Do certified cancer centers provide more cost-effective care? A health economic analysis of colon cancer care in Germany using administrative data
Menée à partir de données 2008-2013 de l'Assurance maladie allemande portant sur 1 909 patients atteints d'un cancer du côlon, cette étude compare le rapport coût-efficacité des soins en cancérologie dans des hopitaux certifiés ou non
Do certified cancer centers provide more cost-effective care? A health economic analysis of colon cancer care in Germany using administrative data
Cheng, Chih-Yuan ; Datzmann, Thomas ; Hernandez, Diego ; Schmitt, Jochen ; Schlander, Michael
Hospital certification has become an important measure to improve cancer care quality, with the potential effect of prolonging patient survival and reducing medical spending. However, yet to be explored is the cost-effectiveness of cancer care provided in certified hospitals, considering significant additional costs incurred from certification requirements. We performed a cost-effectiveness analysis (CEA) using two colon cancer populations (N=1,909) treated in different levels of certified [...]
A partir d'une revue systématique de la littérature (5 évaluations économiques), cette étude présente les résultats des études comparant le rapport coût-efficacité des deux modalités de traitement d'un carcinome épidermoïde oropharyngé de stade T précoce, à savoir la chirurgie robotique trans-orale et la radiothérapie
Economic evaluations comparing Tran-oral robotic surgery and radiotherapy in oropharyngeal squamous cell carcinoma: A systematic review
A partir d'une revue systématique de la littérature (5 évaluations économiques), cette étude présente les résultats des études comparant le rapport coût-efficacité des deux modalités de traitement d'un carcinome épidermoïde oropharyngé de stade T précoce, à savoir la chirurgie robotique trans-orale et la radiothérapie
Economic evaluations comparing Tran-oral robotic surgery and radiotherapy in oropharyngeal squamous cell carcinoma: A systematic review
Thankappan, Krishnakumar ; Battoo, Azhar Jan ; Vidhyadharan, Sivakumar ; Kudpaje, Akshay ; Balasubramanian, Deepak ; Iyer, Subramania
Background: Trans-oral robotic surgery (TORS) and primary radiotherapy are the two modalities used to treat early T stage oropharyngeal squamous cell carcinoma(OPSCC). Prior literature including a recent randomized controlled trial have not shown the superiority of one modality over the other. When the modalities have similar outcomes, cost-effectiveness have an important role in deciding on the appropriate treatment. There are economic evaluations comparing the two modality with contradicting [...]
Ressources et infrastructures (Lutte contre les cancers) (1)
Mené aux Pays-Bas entre 2015 et 2018 sur 353 patients atteints d'un cancer du côlon de stade I-III ou d'un carcinome recto-sigmoïde traité par chirurgie (durée médiane de suivi : 12,2 mois), cet essai randomisé multicentrique de phase II compare la qualité de vie des patients ayant été suivis après le traitement par un médecin généraliste ou par un chirurgien
Effect of general practitioner-led versus surgeon-led colon cancer survivorship care, with or without eHealth support, on quality of life (I CARE):...
Mené aux Pays-Bas entre 2015 et 2018 sur 353 patients atteints d'un cancer du côlon de stade I-III ou d'un carcinome recto-sigmoïde traité par chirurgie (durée médiane de suivi : 12,2 mois), cet essai randomisé multicentrique de phase II compare la qualité de vie des patients ayant été suivis après le traitement par un médecin généraliste ou par un chirurgien
Effect of general practitioner-led versus surgeon-led colon cancer survivorship care, with or without eHealth support, on quality of life (I CARE): an interim analysis of 1-year results of a randomised, controlled trial
Vos, Julien A. M. ; Duineveld, Laura A. M. ; Wieldraaijer, Thijs ; Wind, Jan ; Busschers, Wim B. ; Sert, Edanur ; Tanis, Pieter J. ; Verdonck-de Leeuw, Irma M. ; van Weert, Henk C. P. M. ; van Asselt, Kristel M.
Background: Colon cancer is associated with an increased risk of physical and psychosocial morbidity, even after treatment. General practitioner (GP) care could be beneficial to help to reduce this morbidity. We aimed to assess quality of life (QOL) in patients who received GP-led survivorship care after treatment for colon cancer compared with those who received surgeon-led care. Furthermore, the effect of an eHealth app (Oncokompas) on QOL was assessed in both patient groups. Methods: We did [...]
Who should manage post-treatment care for patients with colon cancer: surgeons or general practitioners?
Mené aux Pays-Bas entre 2015 et 2018 sur 353 patients atteints d'un cancer du côlon de stade I-III ou d'un carcinome recto-sigmoïde traité par chirurgie (durée médiane de suivi : 12,2 mois), cet essai randomisé multicentrique de phase II compare la qualité de vie des patients ayant été suivis après le traitement par un médecin généraliste ou par un chirurgien
Who should manage post-treatment care for patients with colon cancer: surgeons or general practitioners?
Angenete, Eva
In The Lancet Oncology, Julien A M Vos and colleagues 1 have tried to answer an important question with the I CARE study: who should oversee follow-up care for patients with colon cancer? Follow-up after colorectal cancer treatment has previously been studied in several randomised clinical trials, with the aim of providing an evidence base for a follow-up algorithm. 2 However, the primary endpoints of these trials was often detection of recurrence or survival. So far, no study or meta-analysis [...]
